Universität zu Köln

Sailer, Verena, Holmes, Emily Eva, Gevensleben, Heidrun, Goltz, Diane, Droege, Freya, Franzen, Alina, Dietrich, Joern, Kristiansen, Glen, Bootz, Friedrich, Schroeck, Andreas and Dietrich, Dimo (2017). PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma. Clin. Epigenetics, 9. LONDON: BMC. ISSN 1868-7083

Full text not available from this repository.

Abstract

Background: Molecular biomarkers assisting risk-group assignment and subsequent treatment stratification are urgently needed for patients with squamous cell cancer of the head and neck region (HNSCC). Aberrant methylation is a frequent event in cancer and, therefore, a promising source for potential biomarkers. Here, the methylation status of the paired-like homeodomain transcription factor 3 (PITX3) was evaluated in HNSCC. Methods: Using a quantitative real-time PCR, PITX3 methylation was assessed in a cohort of 326 HNSCC patients treated for localized or locally advanced disease (training cohort). The results were validated with Infinium HumanMethylation450 BeadChip data from a 528 HNSCC patient cohort (validation cohort) generated by The Cancer Genome Atlas (TCGA) Research Network. Results: PITX3 methylation was significantly higher methylated in tumor compared to normal adjacent tissue (NAT; training cohort: median methylation NAT 32.3%, tumor 71.8%, p < 0.001; validation cohort: median methylation NAT 16.9%, tumor 35.9%, p < 0.001). PITX3 methylation was also significantly correlated with lymph node status both in the training (p = 0.006) and validation (p < 0.001) cohort. PITX3 methylation was significantly higher in HPV-associated (p16-positive) tumors compared to p16-negative tumors (training cohort: 73.7 vs. 66.2%, p = 0.013; validation cohort: 40.0 vs. 33.1%, p = 0.015). Hypermethylation was significantly associated with the risk of death (training cohort: hazard ratio (HR) = 1.80, [95% confidence interval (CI) 1.20-2.69], p = 0.005; validation cohort: HR = 1.43, [95% CI 1.05-1.95], p = 0.022). In multivariate Cox analyses, PITX3 added independent prognostic information. Messenger RNA (mRNA) expression analysis revealed an inverse correlation with PITX3 methylation in the TCGA cohort. Conclusions: PITX3 DNA methylation is an independent prognostic biomarker for overall survival in patients with HNSCC and might aid in the process of risk stratification for individualized treatment.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sailer, Verena UNSPECIFIED UNSPECIFIED UNSPECIFIED Holmes, Emily Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Gevensleben, Heidrun UNSPECIFIED UNSPECIFIED UNSPECIFIED Goltz, Diane UNSPECIFIED UNSPECIFIED UNSPECIFIED Droege, Freya UNSPECIFIED UNSPECIFIED UNSPECIFIED Franzen, Alina UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietrich, Joern UNSPECIFIED UNSPECIFIED UNSPECIFIED Kristiansen, Glen UNSPECIFIED UNSPECIFIED UNSPECIFIED Bootz, Friedrich UNSPECIFIED UNSPECIFIED UNSPECIFIED Schroeck, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietrich, Dimo UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-239988
DOI:	10.1186/s13148-017-0317-7
Journal or Publication Title:	Clin. Epigenetics
Volume:	9
Date:	2017
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1868-7083
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROSTATE-CANCER PATIENTS; POSITIVE BREAST-CANCER; PROMOTER HYPERMETHYLATION; CLINICAL VALIDATION; ANTIGEN RECURRENCE; BIOMARKER; GENES; RISK; CHEMOTHERAPY; MULTICENTER Multiple languages Oncology; Genetics & Heredity Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/23998